Neoplanocin A

Neoplanocin A

SCHEMBL30543748

Nc1ncnc2c1ncn2C1C=C(CO)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 12/20 1.00
EZH2 Q15910 1/20 0.66
AHCYL1 O43865 1/20 0.65
ADORA3 P0DMS8 3/20 0.56
DPP4 P27487 1/20 0.56
MEN1 O00255 1/20 0.56
SLC28A1 O00337 1/20 0.56
MAP3K7 O43318 1/20 0.56
SLC28A2 O43868 1/20 0.56
GAPDH P04406 1/20 0.56
MAPK1 P28482 1/20 0.56
ADORA2A P29274 1/20 0.56
ADORA2B P29275 1/20 0.56
ADORA1 P30542 1/20 0.56
STAT6 P42226 1/20 0.56
PI4KA P42356 1/20 0.56
KMT2A Q03164 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PI4K2B Q8TCG2 1/20 0.56
DOT1L Q8TEK3 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Neoplanocin A SCHEMBL863873 1.00 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
Neoplanocin A SCHEMBL30001474 1.00 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
Neoplanocin A SCHEMBL12174034 1.00 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
Neoplanocin A SCHEMBL29708080 1.00 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
Neoplanocin A SCHEMBL17117192 1.00 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
Neoplanocin A SCHEMBL12157269 1.00 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
Neoplanocin A SCHEMBL10469277 1.00 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
Neoplanocin A SCHEMBL10576831 1.00 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
SCHEMBL15396253 0.90 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4
SCHEMBL29711226 0.90 AHCY (1.00) AHCYEZH2AHCYL1ADORA3DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250241906-A1 ANABOLIC DRUGS STIMULATING TYPE II COLLAGEN PRODUCTION FROM CHONDROCYTES OR THEIR PROGENITORS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2025-07-31 US disclosed
WO-2023159062-A2 ANABOLIC DRUGS STIMULATING TYPE II COLLAGEN PRODUCTION FROM CHONDROCYTES OR THEIR PROGENITORS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250241906-A1 ANABOLIC DRUGS STIMULATING TYPE II COLLAGEN PRODUCTION FROM CHONDROCYTES OR THEIR PROGENITORS COL2A1, COL1A1, COL14A1 AHCY 3973/4885EZH2 4226/4885AHCYL1 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.